Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study

I. Herbert (1); D.C. Smith (2); H.C. Pitot (3); J.M. Brill (4); R. Chugh (2); E. Rouits (5); J. Rubin (3); J. Strickler (1); G. Vuagniaux (5); J. Mel Sorensen (4); C. Zanna (5).

Cancer Chemother Pharmacol. 2015 Apr;75(4):851-9. doi: 10.1007/s00280-015-2709-8. Epub 2015 Feb 27

  1. Department of Medicine, Duke University School of Medicine, DUMC 3052, Durham, NC, 27710, USA
  2. University of Michigan, Ann Arbor, MI, USA
  3. Mayo Clinic, Rochester, MN, USA
  4. Ascenta Therapeutics, Malvern, PA, USA
  5. Debiopharm International SA, Lausanne, Switzerland